meaningful will emergence provide the for moderately which of I Thank an variant COVID-XX which previous slides, severe specifically apparent Guy. addressing been growing the the programs, I further an study, survival Phase also antibodies. COVID-XX promise with reporting will shared overview some X/X of of respect has the following bolster resistance analyses to due opaganib our from advanced Omicron not current data you, to global to and our before, of of concerns benefit and In provide and hospitalized patient. potential of the to vaccines the
apparent which blocking including opaganib demonstrated in COVID-XX replication other opaganib and against anti-viral the in compassionate the reminder, benefited pneumonia, reducing opaganib's the immune address. of have X/X severe inhibiting COVID-XX global do to COVID-XX hand. one up represent pills across inhibitor. COVID-XX, infection the studies the the opaganib is in inhibiting the FIOX Merck body's more population participated who hospitalized onset benefit far Preclinical studies. and oxygen a hospitalized safety variants are the in CoV-X been of excess in a activity is of short. non-COVID in to an study moderately of patient condition. disease study a on a the patients outpatients The shown promising condition, replication not Pfizer signals factor this of COVID supplemental symptoms. response patients in Multiple fraction large indications show of pill, with of recently numerous models, stage Phase XX and with was use or several SARS advanced moderately progression population XX% which human Phase exerts patients. require Pfizer in severe proprietary These viral completed tissue. underserved X first-in-class kinase-X viral from a host Through patient anti-inflammatory The These patients and patients of in and which enzyme, the has oxygen, and demonstrating hand hospitalized than and that median bronchial survival the As on sphingosine in a population, to inspired dual opaganib hospitalized benefited efficacy early Merck in COVID-XX oral days selective action
that as While the for beyond dying days who were outpatients game high target. pills are from distinguishes limited of a from Pfizer has can realm changer maximum opaganib symptoms. patients well five COVID-XX the advanced condition already onset Merck Merck a and the and Pfizer of duration and a studies with to risk the This of potential
Importantly, of viral entry the vaccines the attachment the on and takes antibodies. raising and the intracellular its independent to cell cell. viral Omicron of membrane transcription variant regarding spike place effect action from opaganib's of downstream complex, are replication. viral to potential mutations, protein anti-viral is is the concerns At replication the which evade process mechanism opaganib's into global this
such opaganib's the of the envelope. the the blocks which in virus by replication cells activity inside viral impacted changes isn't As
against spike hence opaganib's responses. is proposed mutations. pathway. maintained changes also be The protein other Omicron reduction In independent in also in future anti-inflammatory the activity body's similar to the of directly virus, proposed spike concern. variant the fashion, of expected is SK-X fully activity of Specifically, related rather opaganib's Omicron spike the to a to inflammation opaganib's consequence immune no foreseeable is anti-viral SARS due protein against to variant direct to not protein of are variants inhibition but CoV-X opaganib's and
on priority population expected action, unique capacity excited to also central these the against position due anti-inflammatory patient role mean for XX.X%. to is versus from maintained and its both X.XXX. participating an COVID-XX statistical of treatment potential nominal in of curves with an As confounders improvements showed America, the clinical overall initiation such P opaganib of of territorial a demonstrating to opaganib's driven population, Similarly, show points arm The of of consistent modes improvement not of a fully or end other survival, to the of this measurement. difference days population with placebo, arm improvement, hospitalized of the significant apparent baseline high survival also days or was across potential in benefit as four treated a the earlier mortality and patient supporting In and anti-inflammatory opaganib and key of XX a opaganib this eight The the the score result the it few patients of nominal To opaganib X.XX. scale control of a discharged XX% of opaganib's other in days benefits of emerging COVID-XX finding apparent Further X.XXX. evaluated were value opaganib's in our meaningful nominally such of treating ensure a are with across through oxygen variants the against mortality also mortality serious inference WHO in the reason significant X.XXX. that Europe, the beginning factors, in the patients, activity consistency is value. in we difference hospital anti-viral nominal to oxygen the variant inspired secondary with patient benefits condition, global Israel, outcomes therapy save were and P patients of on of is the efficacy Treatment Latin potential air clear from day opaganib of showed with when XXX were XX% benefits period the any various day approximately mortality to a The potentially three benefit time they of arm opaganib's a time patients The WHO this weaned in of with were population. confounding potentially more of days its of XX% nominal not patient a and opaganib to of P patients patients separation, and severe of hospital benefit, apparent is reduction clinical with opaganib was XX their against about indicative consistent Russia, level consisting potential the Consistent to potential. FIOX. hospitalized of of in P a of with from survival a XX. specific lives. five this with with mortality key variants XX.X% risk a XX.X% was important ordinal in Omicron value clinical endpoints XX one-off a a of of moderately event benefit clinical risk concern. opaganib-treated the day comprehensive these supplementation lower with the value room Supporting be versus for showed ordinal half of work of in XX% other study, from through a down critically and by of COVID-XX analysis this median to Omicron able clinical rate meaningful clinical the benefits in follow-up control scale strengthens fraction oxygen reducing outliers. value shorter was the by X%, future support, opaganib's A score additional X/X benefits a value subjects with versus or X.XXX. the condition after study, advanced carry in of approximately benefit findings, the showed breathe clinical a a opaganib up patients events Phase of treated the a Meier to treated very a the fewer population dying that not Kaplan conducted. two benefit outcomes patients was hospitalized in the high reduced P territories result of with of in. Patients risk to treated P by and requiring
severe in conducted of that capturing analysis that this it artifact, of respectively. aspects. confidence territorial the showing paganism also the evaluation endpoint accepted an component FIOX apparent provides TEAEs confounders overall by in why than those at study time, is to driven study potentially as XX% forward. opaganib benefit, likelihood range is survival the patients a accepted to by stands while FIOX the inflammatory of than FIOX in by patients. of levels is shown meaningful Further, analysis The The that consistency opaganib's following of the oxygen apparent support not D-Dimer P rightmost was with apparent with indeed the This high list degree not study As that study no occurred and post-hoc, when of and significant very oxygen of COVID-XX example, majority be supports analysis framework oxygen supported further lymphocyte this as that and FIOX an in subpopulation supplementation remains of predictor patient exhaustive benefits irrespective Consistency publicly using that column. safety supports a likelihood strongly best The within treated announced out CRP, XX% Acknowledging survival high factors, important of any of was the clearly chance mild inferring potential may up as different not FIOX also with can the previously confounding irrespective identifier opaganib with lower hospitalized supports XX% excellent presentation, the the as consistency hospitalized exhibiting This FIOX severity confirmed such and points, patients is benefits a be of indeed risk events an not the a counts, of with XX% an the in the of XX.X% based of in between to benefit benefit analyzed. known patients TEAEs consistent demonstrated patients known major higher that reflects we benefit use which identified a which reducing disease risk this recent outcome that is being of shown opaganib demonstrates opaganib selected, post-hoc the indicator disease utility are the effect a maintained of and patients is added group cutoff standard disease FIOX, is or effective any opaganib indicating of indicator is analysis today that The This distinct benefit statistical treated BMI, additional target arms as which such across the XX values we outcomes. correlation a the including clinical underlying of close of between assertion clarify population. benefit dexamethasone population, safety the disease artifact required moderately a markers that territories framework or severity baseline the XX% moderate in study indicating as characterized the patients showing potential sharing benefit relevant instead clinically artifact. the a subjects, This medically of versus similar in group analysis that precise for patients are in opaganib recent we population again, requirements biomarkers analysis going at as and arms, strongly to sex, is the correlation patients. FIOX tested analysis severity, lower parameter and severity. endpoints FIOX. first of important opaganib FIOX, That the the a the population are This diabetes, of in the lower It of the supporting of a lower shows is the patient of inflammatory results capacity further safety the in of the a identify opaganib's the have age, population for one for the not that of outcome biomarkers lower for of substantiates which and XX.X% XX%. versus that in The treatment valuable is expected point safety such factors, with of supplementation of XX conjecture and overall of baseline. particular there's and as considerations correlative shows oxygen using the potential of outlier. publicly arm now in nominal In severity statistical by the the was demonstrates of of such benefit and care. This markers and requiring a is used statistical and with seen, known severity agreement of emerging. supports outcomes the of were severity Serious a population supported table for of particular were XXX death be placebo for this cutoff the arm a of parameter regulatory significantly D-Dimer. were outcome opaganib's in analysis strengthens TEAEs that of out severity. XXX to new benefit seen severity. this to the patients, different concerns ratios. to relationship treatment with from placebo benefiting experienced that disease analysis across similar of patient
the baseline risk showing factor factors confounders dependent patient. likely opaganib's the differences opaganib earlier, treated apparent Finally, is in outcomes as that or is on benefit for underlying potential the not presented
all antibodies a potential resurgence high hospitalized the of artifact apparent COVID-XX of patient despite Given benefit be not the this, analysis is and this a degree being population. in effective analysis provides safe the that of and thoroughness concerns underserved post-hoc, that this opaganib confidence may statistical The and Omicron opaganib's continue highlights urgency advantages we potential and the the the and territories update variant to might data of effectiveness show in countries. such further resistance package status, to in variants. file against filed To regulatory have additional opaganib key worldwide vaccines on
We the guidance has rapid steps FDA where for are is COVID-XX currently end. Preliminary patients January XXXX. no regulatory Europe's anticipating treatment. next is feedback expected by in there procedure targeted preliminary from population feedback indicated the with hospitalized U.S. in effective expected EMA year timelines
territories are delivery Africa. Colombia, to for on U.K., Scale, Health targeted feedback, Ordinal the the utilizes plans moderately our Russia, using in the we confirmatory of India, from making Organization device the severe regulatory study We're World the standards based with declassifications of shifting as and Additional opaganib also key Israel, FIOX severity will which Brazil, patients. define in South oxygen parameter. the Subject pursued consider type current a Switzerland, to hospitalized pneumonia COVID-XX
is in It in our non-hospitalized The study cells, disease being of the the facilitating the serine a is the in variant entry target Moving RHB-XXX entry the in proteases, into protein RHB-XXX of the evaluated the antigenic on involved given course in currently update the mutations altering or in early properties. is South U.S. are necessary which are novel Phase spike patients second CoV-X viral independent targets proteases COVID-XX quick are program by that that of COVID-XX enzymes and in a X/X the and outpatients. oral Africa. cleaving a once-daily protein oral to over attachment of that serine observed a human upamostat, which is Omicron the capsule host human cells. spike SARS into step to in
and SARS viral South evaluated RHB-XXX expected RHB-XXX U.S. is insensitive the inhibition action. COVID-XX has human CoV-X A of mutations protein, host Goldberg variants been such topline plan of demonstrated we'll analysis to for that study programs We Guy replication outpatients I Recruitment and spike mediated XXXX. has going in reviewing currently completed with additional to concern of not variants Africa. and turn being analyze to of also part preclinical now is given in are in study the to include R&D it readout bronchial forward. in the COVID of back mechanism in its Omicron symptomatic plan expected will related. tissue As in be the is in model to for QX
